Research programme: small molecule therapeutics - Apexian Pharmaceuticals

Drug Profile

Research programme: small molecule therapeutics - Apexian Pharmaceuticals

Alternative Names: APE/Ref-1 inhibitors - Apexian Pharmaceuticals; APX-2009; APX-2014; APX-2048; APX-2050

Latest Information Update: 25 Oct 2016

Price : $50

At a glance

  • Originator ApeX Therapeutics
  • Developer Apexian Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia
  • Research Cancer

Most Recent Events

  • 24 Oct 2016 ApeX Therapeutics is now called Apexian Pharmaceuticals
  • 02 Nov 2015 Early research in Cancer in USA (unspecified route)
  • 15 Jul 2013 Preclinical trials in Acute lymphoblastic leukaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top